How to choose Pulse Oximeters

From fingertip spot-checkers to ICU-grade continuous monitors — what procurement teams and biomed engineers need to evaluate before they buy.

What this is and who buys it

Pulse oximeters are non-invasive optical devices that estimate functional arterial oxygen saturation (SpO₂) and pulse rate by transmitting red and infrared light through perfused tissue — typically a fingertip, earlobe, or neonatal foot. The category spans an enormous range: consumer wellness gadgets selling for under $30, and multiparameter bedside platforms costing over $8,000 per unit. That range is not just a price difference; it reflects fundamentally different regulatory pathways, accuracy obligations, and clinical appropriateness.

Buyers include hospital biomedical engineering and procurement departments acquiring continuous bedside monitors for ICU and PACU fleets, ASC administrators specifying handheld or tabletop units for sedation monitoring, dental and primary-care clinic owners sourcing fingertip spot-checkers for triage, EMS medical directors evaluating transport-rated handhelds, and DME providers selecting Bluetooth-enabled devices for remote patient monitoring programs. SpO₂ is one of five routinely monitored vital signs in acute care, and an inaccurate reading — or a false-normal in a genuinely hypoxic patient — carries direct patient-safety consequences that make getting this purchase right more than a budget exercise.

Demand has accelerated since COVID-19 elevated public awareness of oxygen saturation. The FDA responded with a January 2025 draft guidance substantially raising the bar for clinical accuracy testing, skin-pigmentation diversity requirements, and labeling precision [S1]. Any procurement cycle starting now should treat that evolving standard as the baseline, not a bonus.

Key decision factors

Sensor accuracy and motion performance is where technical comparison must start. The meaningful number is ARMS (accuracy root-mean-square), published in the device's 510(k) summary — not in a brochure. Industry standard is 2–3% ARMS under no-motion conditions and 3% ARMS in motion; some premium sensor lines claim 1.5% ARMS in motion [S5]. Always request the underlying clinical study report; for ICU or NICU settings where motion artifact and poor perfusion are routine, that sub-percentage gap is clinically material.

Skin-pigmentation performance has become a patient-safety and liability issue that procurement cannot ignore. Peer-reviewed and FDA-reviewed evidence shows that conventional